Inovio expects COVID-19 vaccine U.S. trial data by early second quarter
(Reuters) – U.S. vaccine developer Inovio Pharmaceuticals Inc said on Monday it had completed Phase II enrolment for a mid-to-late stage U.S. trial of its COVID-19 vaccine candidate and expects to report data early in the second quarter.
Inovio said it was testing the impact of its vaccine candidate, IN0-4800, on new SARS-CoV-2 variants, as well as developing next-generation COVID-19 vaccine candidates that could be tailored to known and unknown SARS-CoV-2 variants.
“The pan-COVID candidate is designed to provide protection against the U.K., South African and Brazilian stream as well as potentially the currently unknown SARS-CoV-2 variant,” Inovio senior executive Kate Broderick said.
The vaccine news did not boost Inovio shares, which were down 3% in extended trading.